Andrew Fein

H.C. Wainwright Reaffirms Buy On Epizyme On The Heels Of Disappointing DOT1L Expansion Data

In a research note published today, H.C.

Editor Ben Weinberg — November 7, 2014, 6:28 PM EDT

H.C. Wainwright Maintains Buy On Seattle Genetics On The Back Of 3Q Growth

In a research note released Friday, H.C.

Ben Mahaney, Editor — October 31, 2014, 2:27 PM EDT

H.C. Wainwright Comments On Vertex Pharmaceuticals Following Advisory Committee Vote

In a research report issued today, H.C.

Ben Mahaney, Editor — October 22, 2014, 5:34 PM EDT

H.C. Wainwright Comments On Vertex Pharmaceuticals Following Nature’s Article Release

In a research report issued today, H.C.

Ben Mahaney, Editor — October 14, 2014, 12:53 PM EDT

ProQR Already Represents A Long Opportunity For All Investors With An Interest In CR, Says H.C. Wainwright

In a research note released today, H.C.

Editor Ben Weinberg — October 13, 2014, 6:48 PM EDT

Neptune: Phase 2 Topline Win Welcomes Neptune Into Prescription Omega-3 League, Says H.C. Wainwright

In a research report released Friday, analyst Andrew Fein of H.C.

Scott Fields Scott Fields — October 3, 2014, 10:57 AM EDT

H.C. Wainwright Maintains Buy On Seattle Genetics On The Heels Of Positive Data From Phase 3

In a research note published today, H.C.

Corey Williams — September 30, 2014, 2:20 PM EDT

Scarcity Value Inherent In CPRX Story Remains Underappreciated, Says H.C. Wainwright

In a research note released today to investors, H.C.

Ben Mahaney, Editor — September 30, 2014, 2:02 PM EDT

Threshold: We Regard The IDMC Green Light Positively, Says H.C. Wainwright

In a research report issued today, analyst Andrew Fein of H.C.

Ben Mahaney, Editor — September 23, 2014, 4:04 PM EDT

H.C. Wainwright Maintains Buy On Catalyst Pharma, Increases PT To $13

In a research note released yesterday, H.C.

Editor Ben Weinberg — September 16, 2014, 8:07 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts